About Us
Establishment of a company
CellBion Co., Ltd. was founded in July 2010 with the goal of innovating the radiopharmaceutical industry. Since its inception, CellBion has been committed to improving patient outcomes and advancing medical services through continuous innovative research and cutting-edge technology, focusing on the development and commercialization of radiopharmaceuticals to meet unmet medical needs.
History
April 2026Pangyo R&D Center Factory Registration (Korea Industrial Complex Corporation - KICOX)
Pangyo R&D Center Radioisotope Use and Sales Permits (Nuclear Safety and Security Commission - NSSC)
Pangyo R&D Center Radioisotope Use and Sales Permits (Nuclear Safety and Security Commission - NSSC)
September 2025IND approval for Phase 1 clinical trial of PSMA-DGUL in combination with KEYTRUDA® (pembrolizumab)
February 2025Signed a clinical collaboration agreement with MSD for the combination of PSMA-DGUL and KEYTRUDA® (pembrolizumab) in Taxane-Naive Patients with mCRPC
October 2024Listed on KOSDAQ
August 2024Selection of Outstanding Venture Companies. (Korea Venture Business Association)
January 2024Designated as an excellent corporate research institute. (Ministry of Science and ICT)
November 2023Awarded the Minister of Science and ICT Award (No. 23-03517).
July 2023PSMA-DGUL designated as the 11th drug in the Global Innovative Product Fast Track Review System (GIFT).
May 2023Initiation of Phase 3 clinical trial for prostate cancer diagnosis (NGUL) and Phase 2 clinical trial for Tc-MSA.
August 2021Completion of Phase 1 clinical trial for prostate cancer diagnosis and selection for KDDF project (DGUL, Phase 1/2 clinical trial ongoing).
March 2020IND approval for Phase 1 clinical trial for prostate cancer diagnosis (NGUL) and Phase 1/2 clinical trial for prostate cancer treatment (DGUL).
September 2019Comparative researcher trial for PSMA-NGUL (India) and IND approval for Phase 1 clinical trial for Tc-MSA.
September 2018Awarded the Minister of Science and Technology Award (No. 25635).
August 2018IND approval for Phase 1 clinical trial for Tc-99m-MSA (KFDA, No. 31789).
May 2018Selected as a promising bio intellectual property (IP) company by the Ministry of Trade, Industry, and Energy.
February 2018Selected for the New Drug Development Program by the Ministry of Health and Welfare.
January 2017Registration for pharmaceutical wholesale and cosmetic manufacturing license.
December 2016Awarded the Minister of Trade, Industry and Energy Award as an Outstanding Bio R&D Company of 2016.
May 2016Establishment of a Bio R&D Center at Bundang Seoul National University Hospital Healthcare Innovation Park.
December 2015Project MSA designated as the 5th Pharm-Navi by the Ministry of Food and Drug Safety.
July 2015Recognition of CellBion R&D laboratory (Ministry of Science, ICT and Future Planning/Korea Industrial Technology Association).
June 2015Establishment of a pharmaceutical research institute within the Seoul National University Cancer Research Institute.
June 2015Certified as a venture company by the Korea Venture Capital Association.
October 2014Technology transfer agreement with Seoul National University Industry-Academic Cooperation Foundation for Ga68 NOTA-MSA KIT.
July 2010Establishment of CellBion Co., Ltd.
